Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One-Shot lung radiation: does it spare Patients' quality of life?

NCT ID NCT07441941

Symptom relief Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks quality of life in 190 people with inoperable lung tumors or up to 3 lung metastases who receive a single high-dose radiation treatment. Participants fill out questionnaires before treatment and at several points over a year to measure symptoms like breathing trouble, chest pain, and fatigue. The goal is to understand how this convenient one-time treatment affects daily well-being.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 190 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Prospective part: The target population for the prospective part of the study consists of patients aged 18 years or older, treated at ICM or ICL for peripheral T1-2 N0 non-small cell lung carcinoma or non-operable oligometastatic secondary lesions, managed with stereotactic body radiotherapy (SBRT). Retrospective part: The target population for the retrospective part of the study consists of patients aged 18 years or older, treated at ICM or ICL for peripheral T1-2 N0 non-small cell lung carcinoma or non-operable oligometastatic secondary lesions, managed with stereotactic body radiotherapy (SBRT) between July 2020 and August 2025.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: ≥ 18 years * Patient receiving single-fraction stereotactic body radiation therapy (SBRT) * Stage T1-2 N0 M0 non-small cell lung cancer (NSCLC) (AJCC 6th edition) or oligometastatic lung tumor defined by ≤ 3 lung metastasis. * Inoperability: Tumor is inoperable or patient refuses surgery * Tumor size: ≤ 3 cm * Peripheral tumors: \> 2 cm from proximal bronchial tree but ≥ 0.5 cm from the wall * Histologically proven or with evolution criteria (CT scan and PET scan) * ECOG performance status: 0-2 * Ability to comply: Willingness and ability to comply with scheduled visits and other study procedures * Informed consent: Written informed consent obtained * Insurance: Patient is affiliated with a French health insurance plan Exclusion Criteria: * Tumors invading the pleura or mediastinum. * Concurrent infectious pneumonia or pericarditis. * Prior radiotherapy to the treatment field. * Presence of neoadjuvant treatment for the present cancer. * Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results * Patients under guardianship, curatorship or safeguard of justice, * Pregnant or breast-feeding subjects * Concomitant participation or participation within the last 30 days in another clinical trial * Patient with an estimated life expectancy of less than 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (non-small cell lung cancer) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (non-small cell lung cancer) Oligometastatic lung tumor SBRT

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lorraine Cancer Institute

    NOT_YET_RECRUITING

    Vandœuvre-lès-Nancy, 54519, France

  • Montpellier Cancer Institut

    RECRUITING

    Montpellier, ICM, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.